Together with four other groups from our research institute we have been awarded a large collaborative grant to investigate how cancer stem cells scape chemotherapy treatment. This project will also work towards the development of new tools to efficiently eliminate these cells. The Spanish national institute for health research (Instituto Carlos III) has awarded this project, which is led by Dr. R. Mangues.
On March 25th the Seminar Series entitled ‘Neuronal Signaling and Synapses’ will start.
This series ambitions to become a forum of discussion on the latest research performed on the molecular biology of synaptic function.
We will invite speakers from Catalonia, but also from the rest of Spain and Europe.
The complete calendar for 2015 can be viewed here.
On the 28th of December our last publication hits the top one on the list of Most Viewed Molecular Brain papers.
Human post-mortem synapse proteome integrity screening for proteomic studies of postsynaptic complexes.
Bayés A, Collins MO, Galtrey CM, Simonnet C, Roy M, Croning M, Gou G, van de Lagemaat LN, Milward D, Whittle IR, Smith C, Choudhary JS, Grant S.
Mol Brain. 2014 Nov 28;7(1):88.
On January 2015 the Spanish network on Synaptic Dysfunctions in Cognitive Disorders, coordinated by our group, will start its activities.
This recently established network is constituted by 10 Spanish research laboratories located in Barcelona, Madrid, Alicante, Sevilla and Pamplona, and is designed to foster interdisciplinary basic research to study how synaptic dysfunction contributes to cognitive disorders and to identify new targets for future therapeutic interventions.
The ‘Fundació La Marató de TV3’ has awarded a grant to a research project lead by Dr. Alberto Lleó, from the IIB Sant Pau, in which our group also participates. This project will study the proteome of the cerebrospinal fluid in the context of Alzhemier’s Disease, with the goal to identify new prognostic and diagnostic markers.
Nature paper adds further evidence for a causative role of postsynaptic genes in autism spectrum disorders.
This study has found potentially causative mutations in the two genes that our laboratory is working on: SYNGAP1 and SHANK2.